gms | German Medical Science

61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010
Joint Meeting mit der Brasilianischen Gesellschaft für Neurochirurgie am 20. September 2010

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

21. - 25.09.2010, Mannheim

Association of the CC genotype of the regulatory Bcl-2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme

Meeting Abstract

  • Nicolai El Hindy - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland
  • Hagen S. Bachmann - Institut für Pharmakogenetik, Universität Duisburg-Essen, Essen, Deutschland
  • Nicole Lambertz - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland
  • Ulrich Sure - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland
  • Winfried Siffert - Institut für Pharmakogenetik, Universität Duisburg-Essen, Essen, Deutschland
  • I. Erol Sandalcioglu - Abteilung für Neurochirurgie, Universität Duisburg-Essen, Essen, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010. Mannheim, 21.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocV1540

DOI: 10.3205/10dgnc017, URN: urn:nbn:de:0183-10dgnc0174

Veröffentlicht: 16. September 2010

© 2010 El Hindy et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Bcl-2 plays a key role in the downregulation of apoptosis and proliferation, as well as increased chemoresistance in glioblastoma multiforme (GBM). We investigated the role of a common regulatory single-nucleotide polymorphism (-938C>A) which is located in the inhibitory P2 promoter of Bcl-2.

Methods: 160 patients suffering from GBM were retrospectively investigated. Inclusion criteria were availability of DNA and for patients still alive a follow-up of at least 24 months. The results were evaluated with respect to the basic clinical data, type of surgical intervention (gross total resection versus biopsy), adjuvant therapy, MGMT-promoter methylation as well as survival at the 2-year follow-up.

Results: At the two-year follow-up 127 (79.4%) of the 160 patients had died. Kaplan-Meier curves revealed a significantly higher rate of survival for homo- and heterozygous C-allele carriers (p=0.031). In the gross total resection subgroup the survival rate was 47.1% for homozygous C-allele carriers, 32.0% for heterozygous C-allele carriers, but only 21.4% for homozygous A-allele carriers (p=0.024). The stereotactic-biopsy subgroup showed no genotype-dependent differences. Multivariable Cox regression identified the Bcl-2 (-938AA) genotype as an independent negative prognostic factor for 2-year survival in the gross total resection subgroup according to the Bcl-2 (-938CC) genotype reference group (hazard ratio, 2.5; 95% CI, 1.1–5.5; p=0.022).

Conclusions: These results suggest the (-938C>A) polymorphism as a survival prognosticator as well as a marker for a high-risk group within patients with GBM and gross total resection.